| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hydroxamic Acids | 29 | 2014 | 442 | 2.980 |
Why?
|
| Histone Deacetylase Inhibitors | 25 | 2015 | 612 | 2.630 |
Why?
|
| Leukemia, Myeloid, Acute | 32 | 2024 | 6915 | 2.600 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 3 | 2023 | 197 | 2.270 |
Why?
|
| Myeloproliferative Disorders | 7 | 2022 | 767 | 1.920 |
Why?
|
| Drug Synergism | 29 | 2022 | 1313 | 1.700 |
Why?
|
| HSP90 Heat-Shock Proteins | 19 | 2014 | 196 | 1.690 |
Why?
|
| Histone Deacetylases | 13 | 2016 | 365 | 1.500 |
Why?
|
| Antineoplastic Agents | 23 | 2023 | 14289 | 1.450 |
Why?
|
| Indoles | 21 | 2019 | 1009 | 1.400 |
Why?
|
| Histone Demethylases | 3 | 2023 | 144 | 1.360 |
Why?
|
| Enzyme Inhibitors | 15 | 2017 | 1879 | 1.310 |
Why?
|
| Sulfonamides | 10 | 2022 | 1823 | 1.280 |
Why?
|
| Transcription Factors | 13 | 2023 | 5270 | 1.190 |
Why?
|
| Cell Cycle Proteins | 12 | 2023 | 2045 | 0.980 |
Why?
|
| Histone-Lysine N-Methyltransferase | 4 | 2023 | 461 | 0.960 |
Why?
|
| Nuclear Proteins | 14 | 2023 | 3343 | 0.920 |
Why?
|
| Protein Kinase Inhibitors | 7 | 2022 | 4757 | 0.830 |
Why?
|
| Apoptosis | 30 | 2021 | 7591 | 0.820 |
Why?
|
| Proteins | 3 | 2021 | 1963 | 0.810 |
Why?
|
| Cyclin-Dependent Kinase 9 | 1 | 2022 | 64 | 0.800 |
Why?
|
| DNA-Binding Proteins | 9 | 2021 | 4821 | 0.790 |
Why?
|
| Epigenesis, Genetic | 7 | 2023 | 1399 | 0.770 |
Why?
|
| Cell Line, Tumor | 34 | 2022 | 14551 | 0.770 |
Why?
|
| Proto-Oncogene Proteins | 8 | 2023 | 2488 | 0.730 |
Why?
|
| Tumor Cells, Cultured | 14 | 2022 | 5395 | 0.720 |
Why?
|
| Proteolysis | 2 | 2021 | 370 | 0.710 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 11 | 2024 | 1493 | 0.700 |
Why?
|
| Janus Kinase 2 | 5 | 2016 | 679 | 0.690 |
Why?
|
| Adenosine | 2 | 2012 | 289 | 0.670 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 18 | 2023 | 15862 | 0.660 |
Why?
|
| Xenograft Model Antitumor Assays | 16 | 2021 | 3821 | 0.660 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 4 | 2023 | 1664 | 0.660 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2019 | 275 | 0.610 |
Why?
|
| Azepines | 2 | 2015 | 124 | 0.590 |
Why?
|
| Sirtuin 2 | 1 | 2016 | 19 | 0.580 |
Why?
|
| Peroxiredoxins | 1 | 2016 | 17 | 0.580 |
Why?
|
| Pyrimidines | 9 | 2018 | 3518 | 0.570 |
Why?
|
| Histone Acetyltransferases | 2 | 2017 | 411 | 0.550 |
Why?
|
| Ubiquitins | 1 | 2016 | 86 | 0.550 |
Why?
|
| beta Catenin | 3 | 2020 | 688 | 0.540 |
Why?
|
| Fusion Proteins, bcr-abl | 6 | 2008 | 1094 | 0.500 |
Why?
|
| Mice | 30 | 2024 | 34495 | 0.490 |
Why?
|
| Drug Resistance, Neoplasm | 10 | 2020 | 5178 | 0.480 |
Why?
|
| Auranofin | 1 | 2014 | 38 | 0.480 |
Why?
|
| Animals | 37 | 2024 | 59536 | 0.480 |
Why?
|
| Mice, Inbred NOD | 8 | 2018 | 905 | 0.460 |
Why?
|
| Triazoles | 2 | 2015 | 617 | 0.450 |
Why?
|
| Lymphoma, Mantle-Cell | 4 | 2015 | 713 | 0.450 |
Why?
|
| Acetylation | 14 | 2017 | 508 | 0.440 |
Why?
|
| Neoplastic Stem Cells | 2 | 2019 | 1443 | 0.440 |
Why?
|
| Piperazines | 6 | 2012 | 2101 | 0.440 |
Why?
|
| Polycomb Repressive Complex 2 | 5 | 2012 | 160 | 0.430 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2014 | 204 | 0.430 |
Why?
|
| Hydrazines | 1 | 2014 | 208 | 0.420 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2021 | 2359 | 0.410 |
Why?
|
| HL-60 Cells | 9 | 2011 | 302 | 0.410 |
Why?
|
| Resorcinols | 1 | 2011 | 27 | 0.410 |
Why?
|
| Histones | 8 | 2017 | 1466 | 0.400 |
Why?
|
| Humans | 78 | 2024 | 261506 | 0.400 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 3 | 2022 | 923 | 0.400 |
Why?
|
| Oxidative Stress | 2 | 2016 | 1129 | 0.400 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 3 | 2024 | 217 | 0.390 |
Why?
|
| Isoxazoles | 1 | 2011 | 81 | 0.390 |
Why?
|
| Janus Kinases | 1 | 2012 | 174 | 0.390 |
Why?
|
| Signal Transduction | 15 | 2020 | 11965 | 0.390 |
Why?
|
| Leukemia | 4 | 2010 | 1635 | 0.390 |
Why?
|
| Gene Expression Regulation, Neoplastic | 9 | 2021 | 8873 | 0.380 |
Why?
|
| K562 Cells | 8 | 2009 | 338 | 0.360 |
Why?
|
| Proto-Oncogene Proteins c-akt | 6 | 2013 | 2054 | 0.360 |
Why?
|
| Protein Binding | 8 | 2019 | 3438 | 0.360 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2013 | 1546 | 0.360 |
Why?
|
| Repressor Proteins | 4 | 2014 | 1664 | 0.350 |
Why?
|
| Cell Proliferation | 10 | 2021 | 7226 | 0.350 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 5 | 2012 | 245 | 0.340 |
Why?
|
| Mice, SCID | 7 | 2018 | 1869 | 0.340 |
Why?
|
| Lactams, Macrocyclic | 8 | 2010 | 90 | 0.340 |
Why?
|
| Benzoquinones | 8 | 2010 | 108 | 0.330 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2016 | 1283 | 0.330 |
Why?
|
| HSP70 Heat-Shock Proteins | 5 | 2013 | 161 | 0.330 |
Why?
|
| Pyrazoles | 3 | 2018 | 1471 | 0.330 |
Why?
|
| Imidazoles | 4 | 2016 | 999 | 0.320 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 | 2008 | 2527 | 0.310 |
Why?
|
| Colonic Neoplasms | 1 | 2016 | 1390 | 0.310 |
Why?
|
| Immunoprecipitation | 5 | 2016 | 591 | 0.310 |
Why?
|
| Histone Deacetylase 6 | 7 | 2014 | 44 | 0.310 |
Why?
|
| Breast Neoplasms | 9 | 2016 | 15694 | 0.300 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2023 | 2390 | 0.290 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2009 | 310 | 0.290 |
Why?
|
| Gene Expression Regulation, Leukemic | 3 | 2022 | 560 | 0.280 |
Why?
|
| Thiazoles | 2 | 2008 | 726 | 0.270 |
Why?
|
| Biomarkers, Tumor | 4 | 2021 | 10331 | 0.260 |
Why?
|
| Transcription, Genetic | 3 | 2014 | 3154 | 0.260 |
Why?
|
| Leukemia, Myeloid | 4 | 2021 | 941 | 0.250 |
Why?
|
| MDS1 and EVI1 Complex Locus Protein | 2 | 2023 | 52 | 0.250 |
Why?
|
| Thyroid Neoplasms | 1 | 2016 | 1866 | 0.250 |
Why?
|
| Gene Knockdown Techniques | 5 | 2019 | 1077 | 0.250 |
Why?
|
| Cell Cycle | 6 | 2014 | 2084 | 0.240 |
Why?
|
| Bartonella bacilliformis | 1 | 2003 | 1 | 0.240 |
Why?
|
| Bartonella henselae | 1 | 2003 | 23 | 0.240 |
Why?
|
| STAT5 Transcription Factor | 6 | 2016 | 214 | 0.240 |
Why?
|
| Blood Platelet Disorders | 1 | 2024 | 37 | 0.240 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 6 | 2023 | 801 | 0.230 |
Why?
|
| Cell Survival | 8 | 2019 | 3045 | 0.230 |
Why?
|
| Mutation | 11 | 2023 | 15179 | 0.230 |
Why?
|
| Hematopoietic Stem Cells | 4 | 2019 | 1242 | 0.230 |
Why?
|
| Genes, Bacterial | 1 | 2003 | 236 | 0.220 |
Why?
|
| Estrogen Receptor alpha | 1 | 2007 | 701 | 0.220 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2022 | 71 | 0.210 |
Why?
|
| Gene Silencing | 3 | 2021 | 837 | 0.210 |
Why?
|
| Neoplasm Proteins | 7 | 2012 | 3230 | 0.200 |
Why?
|
| Receptors, Androgen | 3 | 2021 | 878 | 0.200 |
Why?
|
| Promoter Regions, Genetic | 4 | 2014 | 3101 | 0.200 |
Why?
|
| Cytoskeletal Proteins | 1 | 2003 | 492 | 0.200 |
Why?
|
| Cell Cycle Checkpoints | 2 | 2013 | 278 | 0.200 |
Why?
|
| Inhibitor of Apoptosis Proteins | 3 | 2012 | 202 | 0.190 |
Why?
|
| Rifabutin | 3 | 2005 | 25 | 0.190 |
Why?
|
| Escherichia coli Proteins | 1 | 2003 | 359 | 0.190 |
Why?
|
| Blotting, Western | 8 | 2019 | 3536 | 0.190 |
Why?
|
| Adenine | 2 | 2021 | 631 | 0.180 |
Why?
|
| Aminopyridines | 1 | 2022 | 212 | 0.180 |
Why?
|
| RNA, Small Interfering | 6 | 2014 | 2216 | 0.180 |
Why?
|
| Tubulin | 2 | 2011 | 169 | 0.180 |
Why?
|
| Disease Models, Animal | 4 | 2019 | 7222 | 0.180 |
Why?
|
| Quinolines | 2 | 2013 | 383 | 0.180 |
Why?
|
| Transcription Factor 4 | 1 | 2019 | 36 | 0.170 |
Why?
|
| GATA2 Transcription Factor | 2 | 2021 | 68 | 0.170 |
Why?
|
| Transcriptome | 2 | 2021 | 1859 | 0.170 |
Why?
|
| RNA Interference | 3 | 2012 | 1408 | 0.170 |
Why?
|
| Immunoblotting | 3 | 2016 | 886 | 0.170 |
Why?
|
| Endoplasmic Reticulum | 2 | 2010 | 308 | 0.160 |
Why?
|
| Benzimidazoles | 1 | 2022 | 428 | 0.160 |
Why?
|
| Azacitidine | 4 | 2023 | 1149 | 0.160 |
Why?
|
| Melanoma | 1 | 2016 | 5317 | 0.160 |
Why?
|
| Immunoglobulins | 1 | 2019 | 266 | 0.160 |
Why?
|
| Microscopy, Confocal | 3 | 2016 | 663 | 0.160 |
Why?
|
| Chromatin | 3 | 2021 | 942 | 0.160 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2023 | 2979 | 0.160 |
Why?
|
| Gene Rearrangement | 1 | 2022 | 783 | 0.160 |
Why?
|
| Piperidines | 2 | 2021 | 1035 | 0.150 |
Why?
|
| Staurosporine | 3 | 2013 | 143 | 0.150 |
Why?
|
| Bcl-2-Like Protein 11 | 2 | 2014 | 65 | 0.150 |
Why?
|
| Gene Expression | 4 | 2014 | 3570 | 0.150 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2021 | 425 | 0.150 |
Why?
|
| Stress, Physiological | 2 | 2010 | 492 | 0.140 |
Why?
|
| Comet Assay | 1 | 2016 | 59 | 0.140 |
Why?
|
| Oxidants | 1 | 2016 | 49 | 0.140 |
Why?
|
| Apoptosis Regulatory Proteins | 3 | 2014 | 621 | 0.140 |
Why?
|
| Pyridones | 1 | 2019 | 348 | 0.140 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2016 | 212 | 0.140 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 3 | 2004 | 661 | 0.140 |
Why?
|
| Peroxidase | 1 | 2016 | 132 | 0.140 |
Why?
|
| Genes, myc | 2 | 2016 | 358 | 0.140 |
Why?
|
| B7-H1 Antigen | 1 | 2023 | 1022 | 0.140 |
Why?
|
| Nuclear Receptor Coactivator 3 | 2 | 2015 | 383 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2020 | 810 | 0.130 |
Why?
|
| RNA-Binding Proteins | 2 | 2023 | 984 | 0.130 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2016 | 280 | 0.130 |
Why?
|
| bcl-X Protein | 3 | 2011 | 196 | 0.130 |
Why?
|
| Female | 19 | 2023 | 141928 | 0.130 |
Why?
|
| Mice, Nude | 4 | 2019 | 4307 | 0.130 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 2018 | 426 | 0.120 |
Why?
|
| Oximes | 1 | 2016 | 175 | 0.120 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2014 | 566 | 0.120 |
Why?
|
| Binding Sites | 1 | 2019 | 2171 | 0.120 |
Why?
|
| Thioredoxin Reductase 1 | 1 | 2014 | 15 | 0.120 |
Why?
|
| Reactive Oxygen Species | 3 | 2014 | 987 | 0.120 |
Why?
|
| Nuclear Receptor Coactivator 1 | 1 | 2015 | 236 | 0.120 |
Why?
|
| Nuclear Receptor Coactivators | 1 | 2014 | 76 | 0.120 |
Why?
|
| U937 Cells | 3 | 2011 | 171 | 0.120 |
Why?
|
| Niacinamide | 1 | 2016 | 421 | 0.120 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 1 | 2014 | 102 | 0.120 |
Why?
|
| Nuclear Receptor Coactivator 2 | 1 | 2015 | 210 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2014 | 125 | 0.120 |
Why?
|
| Co-Repressor Proteins | 1 | 2014 | 122 | 0.120 |
Why?
|
| Zebrafish | 1 | 2016 | 463 | 0.120 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2016 | 371 | 0.120 |
Why?
|
| Genes, bcl-2 | 1 | 2014 | 166 | 0.120 |
Why?
|
| Class III Phosphatidylinositol 3-Kinases | 1 | 2013 | 12 | 0.120 |
Why?
|
| Imatinib Mesylate | 3 | 2006 | 1665 | 0.110 |
Why?
|
| Molecular Targeted Therapy | 2 | 2021 | 2330 | 0.110 |
Why?
|
| Cell Nucleus | 1 | 2018 | 1620 | 0.110 |
Why?
|
| Phagosomes | 1 | 2013 | 72 | 0.110 |
Why?
|
| SKP Cullin F-Box Protein Ligases | 1 | 2012 | 42 | 0.110 |
Why?
|
| Pyrrolidines | 1 | 2013 | 113 | 0.110 |
Why?
|
| Molecular Chaperones | 2 | 2012 | 264 | 0.110 |
Why?
|
| Nitriles | 2 | 2018 | 906 | 0.110 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2012 | 76 | 0.110 |
Why?
|
| Aurora Kinase B | 1 | 2012 | 68 | 0.110 |
Why?
|
| Drug Combinations | 3 | 2009 | 621 | 0.110 |
Why?
|
| Benzamides | 3 | 2006 | 1832 | 0.110 |
Why?
|
| Phenylurea Compounds | 1 | 2016 | 580 | 0.110 |
Why?
|
| Aurora Kinases | 1 | 2012 | 189 | 0.110 |
Why?
|
| Chloroquine | 1 | 2012 | 53 | 0.110 |
Why?
|
| Protein Kinases | 3 | 2014 | 874 | 0.100 |
Why?
|
| RNA, Messenger | 5 | 2016 | 6150 | 0.100 |
Why?
|
| Cells, Cultured | 4 | 2014 | 5637 | 0.100 |
Why?
|
| Pyridazines | 1 | 2014 | 293 | 0.100 |
Why?
|
| MAP Kinase Signaling System | 1 | 2016 | 848 | 0.100 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2015 | 1756 | 0.100 |
Why?
|
| Thrombocythemia, Essential | 1 | 2013 | 162 | 0.100 |
Why?
|
| Drug Resistance | 1 | 2013 | 587 | 0.100 |
Why?
|
| BRCA1 Protein | 1 | 2014 | 493 | 0.100 |
Why?
|
| Aurora Kinase A | 1 | 2012 | 202 | 0.100 |
Why?
|
| Protein Processing, Post-Translational | 4 | 2021 | 803 | 0.100 |
Why?
|
| Cluster Analysis | 1 | 2014 | 1053 | 0.100 |
Why?
|
| Membrane Proteins | 3 | 2014 | 2819 | 0.100 |
Why?
|
| Transcription Factor CHOP | 1 | 2010 | 25 | 0.100 |
Why?
|
| Cell Differentiation | 3 | 2011 | 4078 | 0.090 |
Why?
|
| Multiprotein Complexes | 1 | 2013 | 395 | 0.090 |
Why?
|
| Receptor, trkA | 1 | 2010 | 35 | 0.090 |
Why?
|
| Polycythemia Vera | 1 | 2013 | 238 | 0.090 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2014 | 1064 | 0.090 |
Why?
|
| MicroRNAs | 2 | 2015 | 2947 | 0.090 |
Why?
|
| Isothiocyanates | 1 | 2010 | 44 | 0.090 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2014 | 479 | 0.090 |
Why?
|
| Antigens, CD34 | 1 | 2011 | 593 | 0.090 |
Why?
|
| Proteasome Endopeptidase Complex | 6 | 2011 | 589 | 0.090 |
Why?
|
| Milk Proteins | 3 | 2004 | 116 | 0.090 |
Why?
|
| Autophagy | 2 | 2013 | 927 | 0.090 |
Why?
|
| Carrier Proteins | 2 | 2009 | 2022 | 0.090 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2013 | 1678 | 0.090 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2009 | 83 | 0.090 |
Why?
|
| Gene Dosage | 1 | 2012 | 829 | 0.090 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2011 | 363 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2009 | 639 | 0.080 |
Why?
|
| Gene Expression Profiling | 3 | 2019 | 5159 | 0.080 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2014 | 755 | 0.080 |
Why?
|
| Nitrophenols | 1 | 2008 | 92 | 0.080 |
Why?
|
| Heat-Shock Proteins | 1 | 2010 | 311 | 0.080 |
Why?
|
| Receptors, CXCR4 | 1 | 2010 | 269 | 0.080 |
Why?
|
| MCF-7 Cells | 3 | 2015 | 550 | 0.080 |
Why?
|
| Muscle Proteins | 1 | 2012 | 549 | 0.080 |
Why?
|
| Boronic Acids | 1 | 2010 | 362 | 0.080 |
Why?
|
| Heat Shock Transcription Factors | 1 | 2008 | 51 | 0.080 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2008 | 534 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 10035 | 0.080 |
Why?
|
| Mastocytosis, Systemic | 1 | 2008 | 110 | 0.080 |
Why?
|
| S Phase | 1 | 2008 | 281 | 0.080 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2009 | 503 | 0.080 |
Why?
|
| Biphenyl Compounds | 1 | 2008 | 194 | 0.080 |
Why?
|
| Pyrazines | 1 | 2010 | 495 | 0.080 |
Why?
|
| Phosphorylation | 6 | 2012 | 4804 | 0.080 |
Why?
|
| Receptors, Steroid | 1 | 2008 | 286 | 0.080 |
Why?
|
| Bacterial Proteins | 2 | 2003 | 1029 | 0.080 |
Why?
|
| Polycomb-Group Proteins | 1 | 2006 | 42 | 0.070 |
Why?
|
| Stem Cells | 1 | 2014 | 1213 | 0.070 |
Why?
|
| Protein Methyltransferases | 1 | 2006 | 45 | 0.070 |
Why?
|
| Cisplatin | 1 | 2014 | 2432 | 0.070 |
Why?
|
| DNA Damage | 2 | 2014 | 1954 | 0.070 |
Why?
|
| Base Sequence | 4 | 2010 | 4917 | 0.070 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2009 | 366 | 0.070 |
Why?
|
| Dasatinib | 2 | 2008 | 862 | 0.070 |
Why?
|
| Tumor Burden | 1 | 2012 | 1987 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 1 | 2014 | 1491 | 0.070 |
Why?
|
| Mice, Transgenic | 1 | 2014 | 4143 | 0.070 |
Why?
|
| Lymphoma, B-Cell | 1 | 2012 | 895 | 0.070 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2007 | 324 | 0.070 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2008 | 294 | 0.070 |
Why?
|
| Drug Administration Schedule | 3 | 2018 | 3472 | 0.070 |
Why?
|
| Primary Myelofibrosis | 1 | 2013 | 831 | 0.060 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2003 | 997 | 0.060 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2014 | 1215 | 0.060 |
Why?
|
| Amino Acid Sequence | 3 | 2010 | 4233 | 0.060 |
Why?
|
| Acute Disease | 2 | 2006 | 2422 | 0.060 |
Why?
|
| Transcriptional Activation | 2 | 2021 | 1070 | 0.060 |
Why?
|
| Rhizobiaceae | 1 | 2003 | 2 | 0.060 |
Why?
|
| Peptide Synthases | 1 | 2003 | 7 | 0.060 |
Why?
|
| Down-Regulation | 2 | 2006 | 2074 | 0.060 |
Why?
|
| Protein D-Aspartate-L-Isoaspartate Methyltransferase | 1 | 2003 | 3 | 0.060 |
Why?
|
| src-Family Kinases | 1 | 2006 | 478 | 0.060 |
Why?
|
| Bartonella | 1 | 2003 | 13 | 0.060 |
Why?
|
| Proto-Oncogenes | 1 | 2023 | 202 | 0.060 |
Why?
|
| Tamoxifen | 1 | 2007 | 876 | 0.060 |
Why?
|
| Molecular Sequence Data | 3 | 2010 | 6089 | 0.060 |
Why?
|
| Neoplasms | 3 | 2017 | 15193 | 0.060 |
Why?
|
| Cell Division | 2 | 2005 | 2489 | 0.060 |
Why?
|
| Immune Evasion | 1 | 2023 | 73 | 0.050 |
Why?
|
| Gene Amplification | 1 | 2005 | 731 | 0.050 |
Why?
|
| Genome, Bacterial | 1 | 2003 | 200 | 0.050 |
Why?
|
| Species Specificity | 1 | 2003 | 777 | 0.050 |
Why?
|
| Dilazep | 1 | 2021 | 4 | 0.050 |
Why?
|
| Multigene Family | 1 | 2003 | 425 | 0.050 |
Why?
|
| Checkpoint Kinase 1 | 2 | 2014 | 174 | 0.050 |
Why?
|
| Lipoproteins | 1 | 2003 | 252 | 0.050 |
Why?
|
| DNA Primers | 3 | 2010 | 1399 | 0.050 |
Why?
|
| DNA, Bacterial | 1 | 2003 | 558 | 0.050 |
Why?
|
| Blast Crisis | 1 | 2004 | 557 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2006 | 1819 | 0.050 |
Why?
|
| G1 Phase | 3 | 2009 | 285 | 0.050 |
Why?
|
| Recurrence | 2 | 2023 | 4758 | 0.050 |
Why?
|
| Antigens, Bacterial | 1 | 2003 | 354 | 0.050 |
Why?
|
| Microsatellite Instability | 1 | 2023 | 400 | 0.050 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 2 | 2014 | 430 | 0.050 |
Why?
|
| Cytarabine | 2 | 2023 | 1973 | 0.050 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 1 | 2020 | 41 | 0.050 |
Why?
|
| Male | 10 | 2023 | 123000 | 0.050 |
Why?
|
| Aged | 7 | 2023 | 70117 | 0.040 |
Why?
|
| HEK293 Cells | 2 | 2015 | 1489 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2014 | 287 | 0.040 |
Why?
|
| HeLa Cells | 2 | 2014 | 1643 | 0.040 |
Why?
|
| Acetanilides | 1 | 2018 | 16 | 0.040 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 1 | 2020 | 113 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2014 | 528 | 0.040 |
Why?
|
| Blood Platelets | 1 | 2024 | 731 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2019 | 2291 | 0.040 |
Why?
|
| Drug Substitution | 1 | 2018 | 87 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 1 | 2023 | 966 | 0.040 |
Why?
|
| Febrile Neutropenia | 1 | 2018 | 65 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2023 | 1681 | 0.040 |
Why?
|
| Oncogenes | 1 | 2021 | 673 | 0.040 |
Why?
|
| Polyubiquitin | 2 | 2010 | 23 | 0.040 |
Why?
|
| Prognosis | 2 | 2014 | 21713 | 0.040 |
Why?
|
| Genomic Instability | 1 | 2021 | 519 | 0.040 |
Why?
|
| Treatment Outcome | 4 | 2014 | 32848 | 0.040 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2018 | 146 | 0.040 |
Why?
|
| Aged, 80 and over | 4 | 2023 | 29902 | 0.040 |
Why?
|
| Flow Cytometry | 3 | 2013 | 3033 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2014 | 5767 | 0.040 |
Why?
|
| G2 Phase | 2 | 2009 | 206 | 0.040 |
Why?
|
| Enzyme Activation | 2 | 2011 | 1764 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-raf | 2 | 2008 | 80 | 0.040 |
Why?
|
| Receptors, Interleukin-7 | 1 | 2016 | 44 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2012 | 4938 | 0.040 |
Why?
|
| Middle Aged | 7 | 2023 | 86204 | 0.040 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2023 | 1048 | 0.030 |
Why?
|
| Adenosine Triphosphate | 2 | 2008 | 571 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2010 | 3639 | 0.030 |
Why?
|
| Paclitaxel | 2 | 2014 | 1996 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2014 | 7789 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 6207 | 0.030 |
Why?
|
| Receptor, ErbB-2 | 1 | 2005 | 2518 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2018 | 323 | 0.030 |
Why?
|
| Pancreatic Neoplasms | 1 | 2012 | 5061 | 0.030 |
Why?
|
| Transcription Factor RelA | 1 | 2015 | 184 | 0.030 |
Why?
|
| Liver Neoplasms | 1 | 2011 | 4557 | 0.030 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2014 | 65 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2015 | 129 | 0.030 |
Why?
|
| bcl-2-Associated X Protein | 2 | 2005 | 367 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2015 | 198 | 0.030 |
Why?
|
| Hemorrhage | 1 | 2018 | 712 | 0.030 |
Why?
|
| Caspases | 1 | 2016 | 661 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2019 | 1046 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2018 | 589 | 0.030 |
Why?
|
| Trans-Activators | 3 | 2004 | 1555 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2004 | 259 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2018 | 10001 | 0.030 |
Why?
|
| Tripartite Motif-Containing Protein 28 | 1 | 2013 | 32 | 0.030 |
Why?
|
| Beclin-1 | 1 | 2013 | 85 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2004 | 280 | 0.030 |
Why?
|
| Ubiquitin | 2 | 2005 | 344 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 2283 | 0.030 |
Why?
|
| Sumoylation | 1 | 2013 | 84 | 0.030 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2014 | 467 | 0.030 |
Why?
|
| Fatigue | 1 | 2018 | 1239 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2014 | 666 | 0.030 |
Why?
|
| Cell Growth Processes | 1 | 2012 | 342 | 0.030 |
Why?
|
| Genomics | 1 | 2023 | 2738 | 0.030 |
Why?
|
| Androgens | 1 | 2014 | 511 | 0.020 |
Why?
|
| Phenotype | 1 | 2023 | 6295 | 0.020 |
Why?
|
| Tumor Suppressor p53-Binding Protein 1 | 1 | 2011 | 87 | 0.020 |
Why?
|
| Cell Line | 1 | 2019 | 5114 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2018 | 1960 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2017 | 1299 | 0.020 |
Why?
|
| Methylation | 1 | 2012 | 597 | 0.020 |
Why?
|
| Indole Alkaloids | 1 | 2010 | 7 | 0.020 |
Why?
|
| PC12 Cells | 1 | 2010 | 46 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2013 | 423 | 0.020 |
Why?
|
| Benzylamines | 1 | 2010 | 105 | 0.020 |
Why?
|
| Nerve Growth Factor | 1 | 2010 | 45 | 0.020 |
Why?
|
| HCT116 Cells | 1 | 2011 | 348 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2013 | 702 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 2009 | 3203 | 0.020 |
Why?
|
| Radiation, Ionizing | 1 | 2011 | 187 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2011 | 234 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2013 | 769 | 0.020 |
Why?
|
| Protein Multimerization | 1 | 2011 | 240 | 0.020 |
Why?
|
| Mitochondria | 2 | 2008 | 1282 | 0.020 |
Why?
|
| Carbazoles | 1 | 2010 | 87 | 0.020 |
Why?
|
| Heterocyclic Compounds | 1 | 2010 | 119 | 0.020 |
Why?
|
| Exons | 2 | 2004 | 1328 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2013 | 1290 | 0.020 |
Why?
|
| Adult | 4 | 2023 | 77950 | 0.020 |
Why?
|
| NADPH Oxidases | 1 | 2010 | 146 | 0.020 |
Why?
|
| Peptides, Cyclic | 1 | 2010 | 139 | 0.020 |
Why?
|
| Unfolded Protein Response | 1 | 2010 | 115 | 0.020 |
Why?
|
| Protein Folding | 1 | 2010 | 281 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2013 | 1544 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2011 | 11538 | 0.020 |
Why?
|
| Catalytic Domain | 1 | 2010 | 303 | 0.020 |
Why?
|
| eIF-2 Kinase | 1 | 2010 | 164 | 0.020 |
Why?
|
| Protein Transport | 1 | 2011 | 734 | 0.020 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 1 | 1 | 2008 | 46 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2010 | 626 | 0.020 |
Why?
|
| DNA Probes | 1 | 2008 | 217 | 0.020 |
Why?
|
| Computational Biology | 1 | 2015 | 1271 | 0.020 |
Why?
|
| Bortezomib | 1 | 2010 | 543 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2010 | 717 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2015 | 1549 | 0.020 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2010 | 249 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2008 | 568 | 0.020 |
Why?
|
| Fungal Proteins | 1 | 2009 | 254 | 0.020 |
Why?
|
| Laminin | 1 | 2008 | 194 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2011 | 938 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2010 | 1062 | 0.020 |
Why?
|
| Proteomics | 1 | 2015 | 1380 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2008 | 208 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2008 | 323 | 0.020 |
Why?
|
| Radiation Tolerance | 1 | 2011 | 629 | 0.020 |
Why?
|
| p300-CBP Transcription Factors | 1 | 2008 | 110 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2008 | 549 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2011 | 3251 | 0.020 |
Why?
|
| Cell Death | 1 | 2010 | 671 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2013 | 1694 | 0.020 |
Why?
|
| Ubiquitination | 1 | 2010 | 575 | 0.020 |
Why?
|
| Proteoglycans | 1 | 2008 | 259 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2008 | 256 | 0.020 |
Why?
|
| Membrane Transport Proteins | 1 | 2008 | 244 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2014 | 3001 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2008 | 611 | 0.020 |
Why?
|
| Antioxidants | 1 | 2010 | 507 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2014 | 3005 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2010 | 825 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2010 | 943 | 0.020 |
Why?
|
| Lysine | 1 | 2008 | 422 | 0.020 |
Why?
|
| Pyrrolidinones | 1 | 2005 | 61 | 0.020 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2005 | 119 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2011 | 1265 | 0.020 |
Why?
|
| Benzhydryl Compounds | 1 | 2005 | 85 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2015 | 2669 | 0.020 |
Why?
|
| Biomarkers | 1 | 2016 | 5047 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2011 | 2450 | 0.020 |
Why?
|
| Collagen | 1 | 2008 | 752 | 0.020 |
Why?
|
| Jurkat Cells | 1 | 2004 | 311 | 0.010 |
Why?
|
| Cytokines | 1 | 2013 | 2809 | 0.010 |
Why?
|
| Etoposide | 1 | 2005 | 870 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2013 | 5710 | 0.010 |
Why?
|
| Multienzyme Complexes | 1 | 2004 | 213 | 0.010 |
Why?
|
| DNA Repair | 1 | 2011 | 1872 | 0.010 |
Why?
|
| Cysteine Endopeptidases | 1 | 2004 | 251 | 0.010 |
Why?
|
| Trastuzumab | 1 | 2005 | 696 | 0.010 |
Why?
|
| Open Reading Frames | 1 | 2003 | 250 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2005 | 1258 | 0.010 |
Why?
|
| Remission Induction | 1 | 2008 | 3569 | 0.010 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2003 | 192 | 0.010 |
Why?
|
| Introns | 1 | 2003 | 432 | 0.010 |
Why?
|
| Taxoids | 1 | 2005 | 967 | 0.010 |
Why?
|
| Point Mutation | 1 | 2004 | 769 | 0.010 |
Why?
|
| Rats | 1 | 2010 | 6086 | 0.010 |
Why?
|
| Models, Biological | 1 | 2010 | 3254 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2004 | 1487 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2003 | 1213 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2013 | 9244 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2008 | 3981 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2004 | 1442 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2014 | 13658 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2004 | 1910 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2005 | 1823 | 0.010 |
Why?
|
| Survival Rate | 1 | 2010 | 12221 | 0.010 |
Why?
|
| DNA | 1 | 2004 | 2693 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2005 | 8865 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2004 | 4053 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2005 | 4367 | 0.010 |
Why?
|
| Time Factors | 1 | 2004 | 12926 | 0.010 |
Why?
|